Impact of Piperacillin-Tazobactam Dosing in Septic Shock Patients Using Real-World Evidence: An Observational, Retrospective Cohort Study.

John M AllenDevi SurajbaliDalena Q NguyenJolanta KuczekMaithi TranBrianna HacheyCarinda FeildBethany R Shoulders Steven M SmithStacy A Voils

Published in: The Annals of pharmacotherapy (2022)

In the propensity score-matched cohort, the NORM group had significantly more 28-day NFD. Piperacillin-tazobactam dose reduction in early phase septic shock is associated with worsened clinical outcomes. Clinicians should be vigilant to avoid piperacillin-tazobactam dose reduction in early phase septic shock.

Keyphrases

septic shock
end stage renal disease
gram negative
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
cross sectional
patient reported outcomes
patient reported